Abnormal DNA methylation has been found to be a common feature in cancer cells, although the mechanism of this alteration remains poorly understood. HIC1 is a putative tumour suppressor gene on chromosome 17p13.3 and is hypermethylated in a number of cancers including leukaemia. In this study, using bisulphite genomic sequencing, we have identified a 'boundary' sequence within the HIC1 CpG island that shows a marked junction between methylated and unmethylated DNA in normal haematopoietic cells. Surprisingly, this boundary of differential methylation lies exactly between the intron 2 and exon 3 junction. In contrast to normal haematopoietic cells, hypermethylation extends past this boundary at a high frequency (83%) in newly diagnosed acute myeloid leukaemias (AML). Identification of the hypermethylated boundary sequence not only provides the first step in understanding the mechanisms that normally protect CpG islands from de novo methylation but also may prove to be a useful cancerspecific marker.
Introduction
DNA methylation patterns are often altered in cancer. These changes comprise increased levels of DNA methyltransferase enzyme, 1,2 widespread genomic hypomethylation and simultaneous regional increases in DNA methylation. 3, 4 Hypermethylated regions often harbour CpG island-containing genes such as calcitonin, p15, p16, Rb, VHL, E-cadherin, ER, and HIC1, reviewed in Ref. 5 . HIC1 is a candidate tumour suppressor gene encoding a zinc finger transcription factor belonging to the ZIN family. The HIC1 gene lies distal to p53 on 17p13.3 and centromeric to the area of minimal deletion, which also harbours two putative tumour suppressor genes OVA1 and OVA2. 6 The entire HIC1 gene is CpG rich and is frequently hypermethylated in various cancers, including lung, colon, 7 breast, 8 brain, prostate and leukaemia. 9 Hypermethylation of HIC1 appears to be an early event in prostate, kidney and ovary tumours but has been proposed to be a late event in haematopoietic neoplasms. 9 Also, in contrast to other genes studied in haematopoietic neoplasms such as calcitonin, 10 ER 11 and p15, 12 HIC1 methylation appears to display a relatively disease-specific profile in acute leukaemias. Issa et al 9 reported that the HIC1 is rarely methylated (10%) in acute myeloid leukaemias (AML) but frequently methylated (53%) in acute lymphoblastic leukaemias (ALL).
Methylation studies on HIC1 so far have been limited mainly to restriction analysis of NotI sites spanning an 11 kb region incorporating the HIC1 gene. In order to study the methylation profile of the HIC1 gene in more detail in leuCorrespondence: SJ Clark, CSIRO Molecular Science, Sydney Laboratory, PO Box 184, North Ryde, NSW 1670, Australia; Fax: 612 94905005 Received 10 August 1998; accepted 2 February 1999 kaemia, we have used bisulphite genomic sequencing to characterise the methylation state of the 5Ј untranslated region and the central region of the gene that is heavily CpG rich. In particular, we were interested to determine the methylation pattern in AML patients at diagnosis to see if critical CpG sites were methylated that were undetected by previous restriction analysis. In control bone marrow cells we identified an intron/exon sequence boundary within the HIC1 gene separating methylated and unmethylated DNA. In contrast, this defined methylation boundary no longer existed in the leukaemic cells, instead the CpG rich intron 2 was hypermethylated in the majority of leukaemic patients analysed.
Materials and methods

Tissue samples
Bone marrow samples with blast counts higher than 70% were aspirated from 12 patients with AML. Seven control samples of normal bone marrow were aspirated from the sternal cavity from patients who were undergoing cardiac surgery and who had given prior informed consent. This study was approved by the Ethics Committee of RPAH (protocol number X93-0073).
Methylation analysis
DNA was isolated using TriZOL Reagent (Gibco-BRL, Gaithersburg, MD, USA) from bone marrow cells which had been lysed in hypotonic lysis buffer. Bisulphite genomic sequencing was used to analyse the methylation patterns. The bisulphite reaction was carried out for 16 h at 55°C on 1-2 g of HindIIIdigested patient DNA, under conditions described by Clark et al. 13 After bisulphite conversion, the DNA was ethanol precipitated, dried, resuspended in 100 l TE (10 mM Tris-HCl (pH 8), 1 mM EDTA) and stored at −20°C. Nested PCR amplifications were performed in 50 l reaction mixtures containing 1 l of bisulphite-treated genomic DNA, 200 M of each of the four dNTPs, 300 ng of each primer, 1.5 mM MgCl 2 , 2 units AmpliTaq DNA polymerase (Perkin-Elmer, Norwalk, CT, USA), in a reaction buffer consisting of 67 mM Tris, 16.6 mM ammonium sulphate, 1.7 mg/ml bovine serum albumin and 10 mM B-mercaptoethanol in TE buffer (10 mM Tris/HCl (pH Automated direct sequencing of the HIC1 PCR products was performed using a PRISM Dye Primer Cycle sequencing kit (−21M13 Fwd) with AmpliTaq FS (Perkin-Elmer/ABI, Foster City, CA, USA) on an automated 373A DNA Sequencer (ABI, Foster City, CA, USA). Sequencing reactions were performed as recommended by the manufacturer.
Expression analysis (RT-PCR)
cDNA was reverse transcribed from 1-2 g of total RNA in a 25 l reaction using AMV reverse transcriptase (Promega, Products were electrophoresed on a 1.4% agarose gel. HIC1 was detected by Southern analysis using an internal oligonucleotide probe for HIC1 (661-687) (CTGCAGCAGCAGC TGCCTGGAGTGGCC) that was radiolabelled with ␥ 32 P-ATP and T4-polynucleotide kinase, and visualised after exposure to a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). Rb was detected by incorporation of ␣ 33 P-dATP into the RT-PCR and exposure to a phosphorimager (Molecular Dynamics) after gel electrophoresis.
Results
The HIC1 gene spans 3.6 kb and contains three exons; the first exon is untranslated, the second exon encodes the zincfinger N-terminus (ZIN) and the third exon encodes five zinc fingers 14 ( Figure 1 ). The HIC1 promoter contains a TATAA box sequence 40 bp upstream to the transcription start site. The entire HIC1 gene is G+C rich and has a large CpG island spanning the body of the gene (Figure 1 ). This is in contrast to most CpG island genes that typically span the promoter and the first exon. Previous methylation studies have shown that hypermethylation of the five NotI sites spanning the gene are linked with HIC1 gene silencing in neoplastic cells.
14 Moreover, hypermethylation of these sites has been shown to occur frequently in a number of leukaemia subtypes but was only detected in 10% of AML. 9 To determine if abnormal methylation of the HIC1 gene is more frequent in AML patients at CpG sites not detectable by restriction enzyme analysis, we measured, using bisulphite genomic sequencing, the methylation pattern in the 5Ј untranslated region and in the central CpG rich region spanning intron 2 and exon 3, as shown in Figure 1 . The 5Ј untranslated region contained a single NotI site previously studied by restriction analysis 9 whereas the central CpG rich region does not incorporate any NotI sites and therefore has not been previously analysed. DNA from bone marrow aspirates from 12 patients with AML, and from seven normal control samples was bisulphite treated and the target regions amplified. The HIC1 primers used were shown to amplify both methylated and unmethylated DNA without notable PCR bias, since all CpG sites tested from the 50% methylated PCR control product were methylated at approximately 30-50% (Figure 2a and b) . 15 For the 5Ј untranslated region we measured methylation initially by RsaI digestion of the bisulphitetreated amplified PCR products. RsaI (GTAC) will only digest if the CpG site in the DNA is methylated and converted (ie GCACG is converted to GTACG). Figure 2a shows that 11/12 patient samples and seven normal samples were unmethylated at this site as no digestion was detected, whereas digestion was detected in the spiked 50% methylated DNA sample. We confirmed the lack of methylation in the AML and normal samples at 13 other CpG sites (including a NotI site) in the 5Ј untranslated region by directly sequencing the PCR fragments (Figure 2c ). This was not totally unexpected as Issa et al 9 reported only 10% methylation in AML patients surveyed by restriction enzyme analysis.
However, since the 5Ј untranslated region of the HIC1 gene that was analysed was relatively devoid of CpG sites and appeared to flank the CpG island sequence, we decided to expand our methylation studies to include the central CpGrich region of the HIC1 gene because this region represented a more typical CpG island sequence. We measured the methylation of 45 CpG sites spanning the central CpG-rich region and Figure 3 shows examples of the sequence profiles from AML patients R59 and R63 and from normal bone marrow N35. The methylation state of each cytosine was quantitated by comparing the peak height of the cytosine signal with the peak height of the cytosine plus thymine signal. Figure 4 summarises the methylation state in all the samples tested in the central region of the HIC1 gene. The first observation is that there is significant methylation of the HIC1 gene in all the AML and all the normal DNA samples sequenced. However, the methylation patterns do vary between DNA samples, for example in AML R74, methylation is sparse throughout the region and the level of methylation is low (ෂ5-25%) at each methylated CpG site, whereas AML R125 is heavily methylated at essentially all the CpG sites assayed. The second observation is that the entire CpG-rich region within the HIC1 gene is methylated in 83% (10 out 12) of AML samples, whereas in all seven normal control samples methylation is restricted to the 3Ј end of the HIC1 gene. In fact, only two AML samples, R99 and R128, had methylation profiles similar to the profiles from normal DNA. The third observation, which is the most provocative, is that there appears to be a distinct sequence boundary between methylated and unmethylated DNA in all of the normal control samples. The methylation boundary lies between CpG sites 16 and 17. Interestingly, these sites also span the sequence boundary between intron 2 and exon 3 of the HIC1 gene (Figures 1 and 4) .
To determine if hypermethylation of intron 2 affected HIC1 expression we determined the transcription levels using RT-PCR on samples which had matched RNA and were shown by PCR not to contain DNA contamination (data not shown). Rb expression was used to control for RNA integrity ( Figure 5 ). Figure 5 shows that a HIC1 RT-PCR product was amplified in the normal and every AML sample analysed, indicating that transcription was being initiated from the unmethylated promoter region. Therefore, methylation of the central CpG-rich region of the HIC1 gene does not directly inhibit expression of the gene.
We found no correlation of the HIC1 hypermethylation profiles with either chromosome abnormalities, age, sex or DNA methyltransferase mRNA levels (data not shown). Bone marrow aspirates from all of the AML samples assayed had elevated levels of DNA methyltransferase mRNA, on average 4-to 5-fold, compared to their normal counterparts. 1 In fact, of the samples tested, AML R99 showed the highest DNA methyltransferase level but was one of the few patient samples that displayed a methylation profile similar to normal control DNA. Unlike calcitonin and oestrogen receptor that are reported to be hypermethylated with increasing age, the HIC1 gene in this core CpG region appears to remain unmethylated in all the normal control DNA from N46 age 19 to N35 age 74.
Extensive HIC1 methylation, spanning intron 2, is not limited to acute myeloid leukaemias. We also have found intron 2 hypermethylation in two out of two myeoplastic dysplasia syndrome (MDS) bone marrow aspirates, four out of seven chronic lymphocytic leukaemia (CLL) bone marrow aspirates, one out of one chronic myelogenous leukaemia (CML) aspirates and two out of three acute lymphocytic leukaemia (ALL) aspirates (data not shown). The fact that extensive methylation spanning the intron/exon boundary was observed in a range of leukaemia subtypes at presentation and not in normal bone marrow suggests that hypermethylation of intron 2 in the HIC1 gene is not disease specific in leukaemia and may indeed be an early event as suggested for other cancer types.
Discussion
HIC1 is a putative tumour suppressor gene on 17p13.3 that has been reported to be hypermethylated in a number of cancers including leukaemia. In this study we have defined a specific region in the HIC1 gene that shows differential methylation between intron 2 and exon 3 in normal haematopoietic cells but becomes hypermethylated at a high frequency (83%) in acute myeloid leukaemic cells.
Previous studies using restriction enzymes have reported that the HIC1 CpG-rich sequence is unmethylated in normal haematopoietic cells but is frequently methylated in advanced stages of ALL and CML but rarely methylated in AMLs. 9 Therefore, it was proposed that HIC1 hypermethylation may be disease and stage specific unlike HIC1 methylation in other tumours characterised. In our studies, we found like Issa et al 9 that the 5Ј end of the HIC1 gene is rarely methylated in AMLs, however, in contrast we have found that hypermethylation of the CpG-rich sequence in intron 2 appears to be a common event in all leukaemia subtypes tested, including AMLs. Moreover, we found that intron 2 methylation is cancer specific and does not occur in normal haematopoetic cells whereas the downstream sequence in exon 3 is methylated in both normal and leukaemic cells. The methylation patterns we have identified in intron 2 and exon 3 would not have been identified previously as the CpG-rich region we sequenced did not contain any NotI sites.
Methylation in the body of the gene is not uncommon and typically does not affect gene transcription. 16, 17 This is also true for the HIC1 gene where intron 2 methylation does not directly silence expression in the AML cells. However, the fact that HIC1 hypermethylation is so highly cancer specific and is localised to the more typical CpG island sequence within the HIC1 gene is intriguing. Equally intriguing is the discovery of the marked boundary of methylation between intron 2 and exon 3 in normal cells. It is possible that the abnormal methylation of intron 2 is an early marker of disease, signalling 'leakage' of methylation across the methylation boundary, and that the spread of methylation to the 5Ј region of the HIC1 gene may be associated with later disease stages. 9 We found little evidence for spreading of methylation into the 5Ј untranslated region, but all our samples were from early presentation, however, Issa et al 9 showed that the 5Ј region is more commonly methylated in relapsed leukaemia patients. Moreover, the spreading of methylation from the 3Ј end of HIC1 gene into intron 2 in the cancer cells does not appear to be simply related to elevated DNA methyltransferase levels in the individual tumours or to the age of patients in normal cells. One of the main questions in understanding the mechanism of DNA methylation is what normally protects CpG islands from methylation and how is this process altered in a cancer cell? The methylation boundary identified in the HIC1 gene, separating essentially methylated DNA from unmethylated DNA, may provide some useful insights. A number of possible mechanisms can be considered. First, the DNA sequence or local DNA conformation may provide a directional de novo methylation or protection signal. In this regard, it is striking that in normal haematopoietic cells the unmethylated CpG sites are located in intron 2 and the methylated CpG sites are in exon 3 with the boundary of differential methylation spanning the intron/exon junction of the HIC1 gene. Both the intron and exon sequences are CpG rich, however, at the intron/exon junction there is a three base hairpin stem. However, small hairpin loop structures are not an uncommon structure in DNA sequences, so it seems unlikely that this structure alone would be sufficient to elicit such a gross methylation change. A second possible mechanism is that a functional boundary exists between intron 2 and exon 3, where active transcription itself may protect CpG methylation. Therefore, an intriguing possibility is that an antisense RNA is transcribed from the CpG-rich intron 2, similar to antisense RNA expression from an intronic CpG island in Igf2r. 18 Possible antisense transcription from intron 2 of the HIC1 gene is supported by two observations. Firstly, we have found two putative Sp1 transcription factor binding sites and a downstream promoter element (DPE) 19 in this region, indicative of a promoter region and secondly, Makos-Wales et al 14 using Northern analysis of HIC1 gene expression reported a smaller 1.1 kb transcript in normal tissues. In addition, the smaller transcript was not detected using probes from exon 3 or the 3Ј untranslated region. We are now in the process of determining if there is an antisense transcript and whether its expression is silenced by hypermethylation of intron 2 in cancer cells. A third possible mechanism is that Sp1 binding sites located in intron 2 are important for protecting intron 2 from methylation as described for the APRT gene. 20, 21 In this regard, Sp1 may be prevented from binding due to abnormal CpCpG methylation in the tumour cells 22 or due to the loss of binding proteins that may interact with Sp1 sites at island borders. 5 The results presented here indicate that HIC1 hypermethylation of intron 2 may provide an important marker for haematological cells that are susceptible to becoming carcinogenic. The reintroduction of a functional HIC1 gene into cell lines has been shown to retard cell growth and promote differentiation of tumour cells.
14 Consequently, early detection of HIC1 methylation may be an important step in the treatment and management of patients with leukaemia.
Figure 4
Summary of the HIC1 methylcytosine quantitation for the central CpG region, compiled from direct PCR sequence analysis. The AML patients (R) and normal controls (N) are identified by laboratory number in the left most column. Age and sex is detailed in the next column: M, male; F, female; NA, not available. CpG sites are numbered along the top row from site 1 to site 45. The shaded boxes indicate the degree of methylation as determined by semi-quantitation of all CpG sites described in Figure 3 . Absence of a symbol indicates that the methylation status at that site was not determined due to sequencing enzyme stoppage. The bold vertical line marks the border between intron 2 and exon 3. The bold horizontal line separates the patient and normal samples. 
